How to devise safety and immunotoxicity assessments for Antibodies
Are you looking to improve your understanding of how your antibodies bind, and how and where glycosylation is taking place?
Dr Jeroen Lammerts van Bueren a Senior Scientist at GenMab recently presented data suggesting where therapeutic mAbs are glycosylated and also what the effect of producing in rodent cell lines is in terms of binding:
Investigating the binding of IgE anti-gal-1.3 alpha-gal antibodies from allergic patients to a panel of therapeutic antibodies
- Non-human a-Gal glycan structures on therapeutic antibodies.
- The interaction between IgE against a-Gal and antibody therapeutics
- Underlying mechanisms
Click here for the full presentation
Do you want to find out more?